Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 7/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 2/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994483 | 0.85 | PIK3CA (0.34) | MTORPIK3CAHAO1CYP1A2CYP2E1 | |
| SCHEMBL1993725 | 0.81 | MTOR (0.36) | MTORPIK3CAHAO1ACKR3CYP1A2 | |
| SCHEMBL1995516 | 0.76 | PADI4 (0.34) | ACKR3CDK9 | |
| SCHEMBL1995514 | 0.76 | PADI4 (0.34) | ACKR3CDK9 | |
| SCHEMBL1993611 | 0.76 | CHRM4 (0.34) | MTORPIK3CAHAO1GRM5 | |
| SCHEMBL1993576 | 0.70 | CHRNB2 (0.38) | MTORPIK3CACYP2A6GRM5 | |
| SCHEMBL1991197 | 0.69 | ACKR3 (0.38) | ACKR3 | |
| SCHEMBL1986973 | 0.68 | CHRNA7 (0.45) | CYP1A2 | |
| SCHEMBL1990026 | 0.68 | JUN (0.37) | ACKR3 | |
| SCHEMBL1990084 | 0.66 | PTGES (0.34) | MTORPIK3CAACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | claimed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2516440-A1 | BRIDGEHEAD AMINE RING -FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRY DISORDERS | Abbott Laboratories (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075487-A1 | BRIDGEHEAD AMINE RING -FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRY DISORDERS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | IDO2, IDO1, TPH2 | MTOR 1889/4885PIK3CA 3539/4885HAO1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.